article 3 months old

Icarus Signal New Entries For Today

FYI | Sep 07 2011

This story features AUSTRALIAN CLINICAL LABS LIMITED. For more info SHARE ANALYSIS: ACL

Daily update on share prices and consensus price targets.

By Rudi Filapek-Vandyck

I checked it again this morning and, just to make extra-sure, I did it again just before I started writing today's update on the Icarus Signal, but it would appear RBS is rating Amcom Telecoms ((AMM)) Buy with a target of $0.32. Why does that matter? Because Amcom's share price today is trading above $0.80 which makes the gap between target and price, with a Buy rating, look a little ridiculous. We can only hope RBS has updated its target in the meantime without us finding out about it.

Amcom shares have now entered the table of stocks trading above target. This, we suspect, has probably more to do with the fact that RBS is the only stockbroker in FNArena's universe who covers the stock. Moelis, who's not in our universe, is equally positive about potential and outlook at Amcom but at least Moelis has a target of $1.00. Fits in better with where the share price is today.

No need pointing out that relying on single broker price targets comes with a higher degree of risk. In the meantime, Icarus warnings have preceded firm rejections for Walter Diversified ((WDS)) and Beach Petroleum ((BPT)), while we also couldn't help but noticing that Monadelphous ((MND)) has returned amongst stocks trading close but below target. Qube Logistics ((QUB)), driven by personalities of the old Patrick Stevedores business, has now also landed on Icarus radar and a combination of falling targets and a rising share price is responsible.

Note there are now 8 stocks trading close to target, while 16 others remain above target. Those numbers are likely to change a lot by tomorrow as today's price action suggests the bargain hunters are back with a vengeance.

FKP Property ((FKP)) saw a falling target but the stock still entered the Bottom 50, joining the likes of Heemskirk ((HSK)), PaperlinX ((PPX)) and Alchemia ((ACL)).

Investors should consider the information and data are provided for research purposes only.

Stocks <3% Below Consensus

Order Symbol Current Price($) Consensus Price($) Difference(%)
1 QUB $ 1.45 $ 1.46 0.69%
2 MND $ 18.60 $ 18.98 2.04%
3 MMX $ 0.55 $ 0.56 2.75%
4 MTS $ 4.09 $ 4.21 2.84%

Stocks Above Consensus

Order Symbol Current Price($) Consensus Price($) Difference(%)
1 AMM $ 0.80 $ 0.32 – 60.00%

Top 50 Stocks Furthest from Consensus

Order Symbol Current Price($) Consensus Price($) Difference(%)
1 CVN $ 0.15 $ 0.50 244.83%
2 PPX $ 0.10 $ 0.34 237.00%
3 OTH $ 0.46 $ 1.50 226.09%
4 ACL $ 0.33 $ 1.06 221.21%
5 KAR $ 3.01 $ 9.18 204.85%
6 PLA $ 0.21 $ 0.62 202.44%
7 NCR $ 0.27 $ 0.78 188.89%
8 RES $ 0.53 $ 1.45 173.58%
9 IFN $ 0.23 $ 0.63 173.48%
10 SLX $ 2.85 $ 7.54 164.39%
11 TXN $ 0.54 $ 1.33 146.30%
12 WEC $ 1.81 $ 4.30 138.23%
13 KGL $ 0.10 $ 0.22 129.17%
14 SMR $ 0.89 $ 2.03 128.09%
15 BTA $ 0.90 $ 1.98 120.00%
16 NXS $ 0.24 $ 0.51 111.67%
17 IVA $ 1.50 $ 3.10 106.67%
18 BND $ 0.88 $ 1.80 105.71%
19 HST $ 0.11 $ 0.22 104.76%
20 TIS $ 0.47 $ 0.95 104.30%
21 IPD $ 0.56 $ 1.14 103.57%
22 IAU $ 1.29 $ 2.60 101.55%
23 GNM $ 0.25 $ 0.50 101.20%
24 TSM $ 0.51 $ 1.02 99.02%
25 RFX $ 1.04 $ 2.04 97.10%
26 AVG $ 0.30 $ 0.58 96.61%
27 HFA $ 0.80 $ 1.56 95.00%
28 BOL $ 0.26 $ 0.49 92.16%
29 HZN $ 0.23 $ 0.44 90.43%
30 LNC $ 2.00 $ 3.75 87.50%
31 MPO $ 0.62 $ 1.15 85.48%
32 QRX $ 1.29 $ 2.38 85.21%
33 AQP $ 3.36 $ 6.20 84.52%
34 PEM $ 0.58 $ 1.05 82.61%
35 BSL $ 0.76 $ 1.37 80.66%
36 DTE $ 0.67 $ 1.20 80.45%
37 AJA $ 2.26 $ 3.93 73.89%
38 GBG $ 0.65 $ 1.12 73.18%
39 TAP $ 0.69 $ 1.19 72.99%
40 RQL $ 0.50 $ 0.86 72.73%
41 HGO $ 0.25 $ 0.43 72.00%
42 PGA $ 0.04 $ 0.06 71.43%
43 GRR $ 0.52 $ 0.89 70.77%
44 AWE $ 1.07 $ 1.80 68.60%
45 MAQ $ 8.19 $ 13.51 64.96%
46 CSV $ 0.83 $ 1.37 64.46%
47 FKP $ 0.52 $ 0.85 62.69%
48 RIO $ 68.21 $ 110.17 61.51%
49 COK $ 0.41 $ 0.66 60.98%
50 HSK $ 0.10 $ 0.16 60.00%

To see the full Icarus Signal, please go to this link

Technical limitations

If you are reading this story through a third party distribution channel and you cannot see charts included, we apologise, but technical limitations are to blame.

Find out why FNArena subscribers like the service so much: "Your Feedback (Thank You)" – Warning this story contains unashamedly positive feedback on the service provided.

Share on FacebookTweet about this on TwitterShare on LinkedIn

Click to view our Glossary of Financial Terms

CHARTS

ACL

For more info SHARE ANALYSIS: ACL - AUSTRALIAN CLINICAL LABS LIMITED